Pharvaris’s Phase III HAE Data Position Deucrictibant For 2026 NDA Filing

 
• By Joseph Haas
  
angioedema word cube with background
Pharvaris's Phase III data has the firm ready to file deucrictibant for FDA approval • Source: Shutterstock

More from Strategy

More from Business